This is a working overview of storage stability, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-15. Anything still debated is marked as such rather than presented as settled.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
=== Central nervous system === In general, adenosine has an inhibitory effect in the central nervous system (CNS). Caffeine's stimulatory effects are credited primarily (although not entirely) to its capacity to block adenosine receptors, thereby reducing the inhibitory tonus of adenosine in the CNS. This reduction in adenosine activity leads to increased activity of the neurotransmitters dopamine and glutamate. Experimental evidence suggests that adenosine and adenosine agonists can activate Trk receptor phosphorylation through a mechanism that requires the adenosine A2A receptor. Adenosine in the brain acts through three major receptor subtypes—A1, A2A, and A3—distributed across various neuronal and glial populations. Activation of neuronal A1 receptors generally exerts inhibitory effects, contributing to synaptic regulation. In a preclinical knock-in model of Alzheimer's disease, neuronal hyperexcitability during the asymptomatic stage has been shown to originate at the synaptic compartment and is associated with a deficient adenosinergic tone, suggesting that impaired adenosine signaling may contribute to early synaptic dysfunction.
=== Impact of nucleation === Nucleation lays the foundation for the nanoparticle synthesis. Initial nuclei play a vital role on the size and shape of the nanoparticles that will ultimately form by acting as templating nuclei for the nanoparticle itself. Long-term stability is also determined by the initial nucleation procedures. Homogeneous nucleation occurs when nuclei form uniformly throughout the parent phase and is less common. Heterogeneous nucleation, however, forms on areas such as container surfaces, impurities, and other defects. Crystals can form simultaneously when nucleation occurs rapidly, resulting in a more uniform (monodisperse) product. In contrast, slow nucleation rates often lead to a diverse (polydisperse) population of crystals with varying sizes. This phenomenon is exemplified in the formation of CaCO3 crystals. Controlling nucleation allows for the control of size, dispersity, and phase of nanoparticles. The process of nucleation and growth within nanoparticles can be described by nucleation, Ostwald ripening or the two-step mechanism-autocatalysis model.
== See also == Substituted methoxyphenethylamine 4-Substituted 2,5-dimethoxyphenethylamines (2Cs) 4-Substituted 2,5-dimethoxyamphetamines (DOx) 4-Substituted 2,5-dimethoxy-α-ethylphenethylamines (4Cs) List of miscellaneous 5-HT2A receptor agonists
== Diagnosis == SJIA is diagnosed clinically and corroborated by typical test findings; it is a diagnosis of exclusion. Other causes of fever, such as infections, cancer, and other inflammatory/rheumatologic disorders such autoinflamatory syndromes, systemic lupus erythematosus, and Kawasaki disease, must be ruled out. When a child is suspected of having sJIA, they should always have a full evaluation for infection and cancer. This evaluation should include blood and urine cultures, imaging tests, and perhaps a bone marrow exam or lymph node biopsy to rule out leukemia or lymphoma. According to the most recent International League of Associations for Rheumatology (ILAR) criteria, a child must have arthritis, ≥2 weeks of daily fever that is documented as occurring daily for ≥3 days, and any one of the following symptoms to be classified as having sJIA: organomegaly, lymphadenopathy, serositis, or non-fixed/evanescent rash While there are typical patterns of laboratory abnormalities, such as elevated C-reactive protein levels, high erythrocyte sedimentation rates, neutrophilia, thrombocytosis, and microcytic anemia, there are no particular laboratory tests for sJIA.
Sources: en.wikipedia.org
Earth The HIC of mantle rocks on Earth is highly variable; and that of mantle water is around −80‰ ~ −50‰ depending on its states such as fluid, hydrous phase, hydroxyl point defect, juvenile water (from degassing of the mantle), magmatic water (water equilibrated with a magma). Sun The Sun's DHR is around 21 ± 5 × 10−6. Mars The current HIC is enriched by a factor of 5 relative to Earth's seawater due to continual losses of H in Martian atmosphere. Therefore, the δD is estimated at around +4000‰. The DHRs of Jupiter and Saturn are nearly in the order of 10−5, and the DHRs of Uranus and Neptune are closer to 10−4. Hydrogen is the most abundant element in the universe. Variations in isotopic composition of extraterrestrial materials stem from planetary accretion or other planetary processes such as atmospheric escape, and are larger for H and N than for C and O. The preservation of D-enrichment is observed in chondritic meteorites, interplanetary dust particles and cometary Volatiles. From the helium isotope abundance data, the cosmic DHR is estimated at around 20 ppm: much lower than the terrestrial DHR of 150 ppm. The enrichment of D/H from the proto-solar reservoir occurs for most of the planets except for Jupiter and Saturn, the massive gaseous planets. The DHRs of the atmospheres of Venus and Mars are ~2 × 10−2 and ~8 × 10−4 respectively. The DHRs of Uranus and Neptune are larger than that of protosolar reservoir by a factor of ~3 due to their deuterium-rich icy cores.
In organisms that use chromosomal crossover to exchange DNA and recombine genes, errors in alignment during meiosis can also cause mutations. Errors in crossover are especially likely when similar sequences cause partner chromosomes to adopt a mistaken alignment; this makes some regions in genomes more prone to mutating in this way. These errors create large structural changes in DNA sequence—duplications, inversions, deletions of entire regions—or the accidental exchange of whole parts of sequences between different chromosomes, chromosomal translocation.
According to Vandewalle, Gaddafi "dominated [Libya's] political life" during his period in power. The sociologist Raymond A. Hinnebusch described the Libyan as "perhaps the most exemplary contemporary case of the politics of charismatic leadership", displaying all of the traits of charismatic authority outlined by the sociologist Max Weber. According to Hinnebusch, the foundations of Gaddafi's "personal charismatic authority" in Libya stemmed from the blessing he had received from Nasser coupled with "nationalist achievements" such as the expulsion of foreign military bases, the extraction of higher prices for Libyan oil, and his vocal support for the Palestinian and anti-imperialist causes. A cult of personality devoted to Gaddafi existed in Libya through most of his rule. His biographer Alison Pargeter noted that "he filled every space, moulding the entire country around himself." Depictions of his face could be found throughout the country, including on postage stamps, watches, and school satchels. Quotations from The Green Book appeared on a wide variety of places, from street walls to airports and pens, and were put to pop music for public release. In private, Gaddafi often complained that he disliked this personality cult surrounding him, but that he tolerated it because the people of Libya adored him. The cult served a political purpose, with Gaddafi helping to provide a central identity for the Libyan state. Several biographers and observers characterized Gaddafi as a populist. He enjoyed attending lengthy, often televised, public sessions where he was questioned.
=== Pre-structured motifs === Unlike globular proteins, IDPs do not have spatially-disposed active pockets. 80% of target-unbound IDPs (~4 dozens) subjected to detailed structural characterization by NMR possess linear motifs termed PresMos (pre-structured motifs) that are transient secondary structural elements primed for target recognition. In several cases it has been demonstrated that these transient structures become full and stable secondary structures, e.g., helices, upon target binding. Hence, PresMos are the putative active sites in IDPs.
== Use in archaeology == In archaeology, hydroxyapatite from human and animal remains can be analysed to reconstruct ancient diets, migrations and paleoclimate. The mineral fractions of bone and teeth act as a reservoir of trace elements, including carbon, oxygen and strontium. Stable isotope analysis of human and faunal hydroxyapatite can be used to indicate whether a diet was predominantly terrestrial or marine in nature (carbon, strontium); the geographical origin and migratory habits of an animal or human (oxygen, strontium) and to reconstruct past temperatures and climate shifts (oxygen). Post-depositional alteration of bone can contribute to the degradation of bone collagen, the protein required for stable isotope analysis.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.